Amgen's Third Quarter 2007 Adjusted Earnings Per Share Increased 4 Percent to $1.08 Read more about Amgen's Third Quarter 2007 Adjusted Earnings Per Share Increased 4 Percent to $1.08
Jury Rules Roche Infringes Amgen's EPO Patents Read more about Jury Rules Roche Infringes Amgen's EPO Patents
Amgen Announces Webcast of 2007 Third Quarter Financial Results Read more about Amgen Announces Webcast of 2007 Third Quarter Financial Results
Amgen and Dompe Biotec to Combine Commercial Operations in Italy Read more about Amgen and Dompe Biotec to Combine Commercial Operations in Italy
Amgen to Postpone Indefinitely Its Plans for a Manufacturing Facility in Ireland Read more about Amgen to Postpone Indefinitely Its Plans for a Manufacturing Facility in Ireland
Amgen Appoints Vance D. Coffman to the Company's Board of Directors Read more about Amgen Appoints Vance D. Coffman to the Company's Board of Directors
Amgen Provides Update on Late-Stage and Early-Stage Pipeline at UBS Global Life Sciences Conference Read more about Amgen Provides Update on Late-Stage and Early-Stage Pipeline at UBS Global Life Sciences Conference
Aranesp(R) (darbepoetin alfa) Approved for Use in All European Paediatric Patients with Chronic Renal Failure Anaemia Read more about Aranesp(R) (darbepoetin alfa) Approved for Use in All European Paediatric Patients with Chronic Renal Failure Anaemia
Amgen Receives Proposal for Amending EU Prescribing Information for Aranesp(R) Read more about Amgen Receives Proposal for Amending EU Prescribing Information for Aranesp(R)
New Analysis Suggests First Cycle Use of Neulasta(R) Reduces Febrile Neutropenia Hospitalizations and Chemotherapy Dose Reductions in Breast Cancer Patients Compared to Current Practice Read more about New Analysis Suggests First Cycle Use of Neulasta(R) Reduces Febrile Neutropenia Hospitalizations and Chemotherapy Dose Reductions in Breast Cancer Patients Compared to Current Practice
